MX2013009459A - Preparacion farmaceutica que contiene selenita o compuestos que contienen selenita para el tratamiento de displasias cervicales o carcinomas. - Google Patents

Preparacion farmaceutica que contiene selenita o compuestos que contienen selenita para el tratamiento de displasias cervicales o carcinomas.

Info

Publication number
MX2013009459A
MX2013009459A MX2013009459A MX2013009459A MX2013009459A MX 2013009459 A MX2013009459 A MX 2013009459A MX 2013009459 A MX2013009459 A MX 2013009459A MX 2013009459 A MX2013009459 A MX 2013009459A MX 2013009459 A MX2013009459 A MX 2013009459A
Authority
MX
Mexico
Prior art keywords
selenite
acid
carcinomas
treating cervical
pharmaceutical preparation
Prior art date
Application number
MX2013009459A
Other languages
English (en)
Other versions
MX342098B (es
Inventor
Norbert Fuchs
Original Assignee
Selo Medical Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Selo Medical Gmbh filed Critical Selo Medical Gmbh
Publication of MX2013009459A publication Critical patent/MX2013009459A/es
Publication of MX342098B publication Critical patent/MX342098B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

La invención se refiere a composiciones que contienen compuestos que contiene selenita y ácidos farmacéuticamente aceptables, seleccionados de ácido cítrico, ácido acético, ácido málico, ácido carbónico, ácido sulfúrico, ácido nítrico, ácido clorhídrico, ácidos de frutas o sus mezclas, para su uso en el tratamiento de inflamaciones cervicales, displasia y/o carcinomas.
MX2013009459A 2011-02-16 2012-02-16 Preparacion farmaceutica que contiene selenita o compuestos que contienen selenita para el tratamiento de displasias cervicales o carcinomas. MX342098B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA201/2011A AT511159A1 (de) 2011-02-16 2011-02-16 Pharmazeutische zusammensetzungen enthaltend selenit- oder selenathältige verbindungen
PCT/AT2012/000032 WO2012109685A1 (de) 2011-02-16 2012-02-16 Pharmazeutische zubereitung enthaltend selenit - oder selenithaltige verbindungen zur behandlung von cervix - dysplasien oder -karzinomen

Publications (2)

Publication Number Publication Date
MX2013009459A true MX2013009459A (es) 2013-12-12
MX342098B MX342098B (es) 2016-09-13

Family

ID=45807993

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013009459A MX342098B (es) 2011-02-16 2012-02-16 Preparacion farmaceutica que contiene selenita o compuestos que contienen selenita para el tratamiento de displasias cervicales o carcinomas.

Country Status (28)

Country Link
US (3) US10201566B2 (es)
EP (1) EP2675432B1 (es)
JP (1) JP5986110B2 (es)
CN (2) CN107582563B (es)
AR (1) AR085265A1 (es)
AT (1) AT511159A1 (es)
AU (1) AU2012219005B2 (es)
BR (1) BR112013020702B1 (es)
CA (1) CA2826999C (es)
CL (1) CL2013002353A1 (es)
CY (1) CY1117768T1 (es)
EA (2) EA025419B1 (es)
ES (1) ES2577150T3 (es)
GE (1) GEP201606590B (es)
HK (1) HK1243360A1 (es)
HR (1) HRP20160891T1 (es)
HU (1) HUE029811T2 (es)
IL (1) IL227981A (es)
ME (1) ME02422B (es)
MX (1) MX342098B (es)
PL (1) PL2675432T3 (es)
PT (1) PT2675432T (es)
RS (1) RS54952B1 (es)
SI (1) SI2675432T1 (es)
SM (1) SMT201600233B (es)
TW (1) TWI538678B (es)
UA (1) UA112767C2 (es)
WO (1) WO2012109685A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012222956A1 (de) * 2012-12-12 2014-06-12 Beiersdorf Ag Kosmetische Zubereitungen mit Fließgrenze
EP3616693A1 (en) * 2018-08-28 2020-03-04 Selo Medical GmbH Therapy of high-risk human papillomavirus infections
WO2021041825A1 (en) * 2019-08-30 2021-03-04 Musc Foundation For Research Development Sphingolipid-based selenium compounds, methods for their preparation, and pharmaceutical uses thereof, including as antitumor agents
EP3875083A1 (en) 2020-03-03 2021-09-08 Selo Medical GmbH Composition for use in a treatment of cervical cell abnormalities comprising selenite compound and acid
CA3183544A1 (en) * 2020-06-26 2021-12-30 Albert B. Crum Compositions and methods for the treatment of covid-19

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1112164A (en) 1977-08-02 1981-11-10 Joseph R. Levitt Therapeutic selenium compositions and the use thereof
US4512977A (en) 1979-10-18 1985-04-23 Lundy Research Laboratories, Inc. Therapeutic selenium compositions and the use thereof
IT1161213B (it) 1983-03-08 1987-03-18 Fcn Srl Composizioni farmaceutiche ad attivita' antineoplastica
US4762726A (en) 1983-12-30 1988-08-09 Kraft, Inc. Shelf stable acid food dressings containing fibrous protein complexes
US4668515A (en) 1984-03-06 1987-05-26 Paul Bankit Method and compositions for sodium selenite administration
US5389677B1 (en) 1986-12-23 1997-07-15 Tristrata Inc Method of treating wrinkles using glycalic acid
US5153230A (en) 1989-10-06 1992-10-06 Perfective Cosmetics, Inc. Topical skin cream composition
US5182104A (en) 1991-07-16 1993-01-26 Stanley Marcus Topical virucidal composition for treatment of mucocutaneous tissue
DK0630192T3 (da) 1992-03-11 1996-12-09 Procter & Gamble Psyllium-drikkeblandingsprodukter indeholdende granuleret base
US5425944A (en) 1992-10-27 1995-06-20 Harich; Jakob Antimicrobial grapefruit extract
US5536497A (en) 1992-12-21 1996-07-16 The Research Foundation Of State University Of New York Fimbrial polypeptides useful in the prevention of periodontitis
DE4320694C2 (de) 1993-06-22 1999-11-11 Biosyn Arzneimittel Gmbh Vewendung von Selenverbindungen zur äußeren Anwendung bei Warzen
US5484612A (en) 1993-09-22 1996-01-16 The Board Of Trustees Of The Leland Stanford Junior University Method of treating a mammal having a solid tumor susceptible to treatment with cisplatin
DE4335441A1 (de) 1993-10-18 1995-04-20 Hans Dipl Chem Heide Mittel zur Gesundheitsvorsorge im Herz- Kreislaufsystem beim Menschen
US5512200A (en) 1994-04-18 1996-04-30 Thomas G. Bongard Low pH Acidic Compositions
DE4413839C1 (de) 1994-04-21 1995-10-19 Fritz Koch Pharma Gmbh Dr Med Kombinationspräparat
EP0750911B1 (en) 1995-06-07 2003-09-10 Life Science Labs, Inc. Composition containing selenium to reduce cancer incidence and extend lifespan
GB2323030A (en) 1997-03-12 1998-09-16 Essential Nutrition Ltd Dietary supplements for immunocompromised patients
US5999844A (en) * 1997-04-23 1999-12-07 Accumed International, Inc. Method and apparatus for imaging and sampling diseased tissue using autofluorescence
US6069152A (en) 1997-10-07 2000-05-30 Eli Lilly And Company 5-HT4 agonists and antagonists
GB9722361D0 (en) 1997-10-24 1997-12-17 Pharma Nord Uk Ltd Pharmaceutical formulation for treating liver disorders
IT1297080B1 (it) 1997-11-26 1999-08-03 Andrea Carnevali Composizione per il trattamento di ustioni, eritemi solari, abrasioni, piaghe e irritazioni cutanee
US6228347B1 (en) 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
FR2779720B1 (fr) 1998-06-12 2002-08-16 Galderma Rech Dermatologique Nouveaux composes diarylselenures et leur utilisation en medecine humaine ou veterinaire ainsi qu'en cosmetologie
US6120758A (en) 1998-07-16 2000-09-19 Shaklee Corporation Preservative system for topically applied products
FR2782642B1 (fr) 1998-08-31 2001-12-07 Xavier Forceville Utilisation du selenium pour le traitement de patients atteints d'un syndrome de reponse inflammatoire systemique (sirs), et composition pour la mise en oeuvre du traitement
US6114348A (en) 1999-03-10 2000-09-05 Weber; Paul J. Method of treating warts using tazarotene
JP2003532608A (ja) 2000-05-10 2003-11-05 オーコファーム フォーシュンクス−ウント エントウィックルングス−ゲゼルシャフト ミット ベシュレンクテル ハフトング 二酸化ケイ素の表面積を低減する方法
AT412758B (de) 2000-06-05 2005-07-25 Vis Vitalis Lizenz & Handels Verwendung einer selenithältigen lösung zur behandlung viraler erkrankungen
AT412448B (de) 2001-02-13 2005-03-25 Vis Vitalis Lizenz & Handels Verwendung von selenhältigen präparaten
AT412703B (de) * 2001-12-04 2005-06-27 Vis Vitalis Lizenz & Handels Verwendung von selenithältigen präparaten zur topischen oder bukkalen anwendung

Also Published As

Publication number Publication date
CA2826999A1 (en) 2012-08-23
US20200206262A1 (en) 2020-07-02
IL227981A (en) 2017-03-30
EP2675432B1 (de) 2016-04-20
WO2012109685A1 (de) 2012-08-23
CA2826999C (en) 2019-01-15
EA025419B1 (ru) 2016-12-30
TW201309308A (zh) 2013-03-01
PT2675432T (pt) 2016-07-26
CN107582563B (zh) 2021-03-19
AU2012219005B2 (en) 2016-08-25
CN103379899A (zh) 2013-10-30
BR112013020702B1 (pt) 2021-09-08
JP2014505708A (ja) 2014-03-06
JP5986110B2 (ja) 2016-09-06
AR085265A1 (es) 2013-09-18
EA033519B1 (ru) 2019-10-31
MX342098B (es) 2016-09-13
SMT201600233B (it) 2016-08-31
EP2675432A1 (de) 2013-12-25
US20130323328A1 (en) 2013-12-05
CN107582563A (zh) 2018-01-16
EA201300910A1 (ru) 2014-02-28
US10543228B2 (en) 2020-01-28
CL2013002353A1 (es) 2014-06-27
CY1117768T1 (el) 2017-05-17
HUE029811T2 (hu) 2017-03-28
UA112767C2 (uk) 2016-10-25
TWI538678B (zh) 2016-06-21
AT511159A1 (de) 2012-09-15
SI2675432T1 (sl) 2016-08-31
ES2577150T3 (es) 2016-07-13
GEP201606590B (en) 2017-01-10
HRP20160891T1 (hr) 2016-09-23
HK1243360A1 (zh) 2018-07-13
ME02422B (me) 2016-09-20
BR112013020702A2 (pt) 2016-10-18
AU2012219005A1 (en) 2013-09-19
EA201691236A1 (ru) 2016-10-31
PL2675432T3 (pl) 2016-10-31
US20190125787A1 (en) 2019-05-02
US10201566B2 (en) 2019-02-12
RS54952B1 (sr) 2016-11-30
IL227981A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
PH12015501108B1 (en) Treatment of pulmonary disease
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
UA109868C2 (ru) Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar)
WO2010139979A3 (en) Processes for preparing crystalline forms of dasatinib
IL232267A (en) Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective
WO2013072932A3 (en) Oral care compositions
GB201118656D0 (en) New compounds
MX2013001677A (es) Formulaciones estables de linaclotida.
WO2011127333A3 (en) Compounds for treating disease, for administering, and for pharmaceutical compositions
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
EP2431366A4 (en) NEW CONJUGATED CHLORINE E6 FOLIC ACID COMPOUND, METHOD OF MANUFACTURING THEREOF AND PHARMACEUTICAL COMPOUNDS THEREOF FOR THE TREATMENT OF CANCER
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
TN2015000007A1 (en) 3-substituted estra-1,3,5(10),16-tetraene derivatives, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
WO2013188268A8 (en) Topical ophthalmological pharmaceutical composition containing pazopanib
MX342098B (es) Preparacion farmaceutica que contiene selenita o compuestos que contienen selenita para el tratamiento de displasias cervicales o carcinomas.
ZA201101517B (en) Compositions for the prophylaxis and treatment of dermatological/mucosal diseases,and uses thereof
SI2247573T1 (sl) Soli ogljikove in Ĺľveplove kisline in 3-(2,2,2-trimetilhidrazin) propionat estrov ter njihova uporaba pri pripravi 3-(2,2,2-trimetilhidrazin) propionat dihidrata
MX2015011588A (es) Tratamiento de combinacion.
IN2014DN09240A (es)
WO2012004588A3 (en) Therapeutic agents 976
WO2009142968A3 (en) Valproic acid salts
WO2012130999A9 (fr) Peptides isolés et purifiés à partir de testicules de roussettes
UA81932U (ru) Комбинированный препарат "ротрин-дента" в виде геля для лечения воспалительных заболеваний слизистой оболочки полости рта
WO2011154975A3 (en) Pharmaceutical compositions of metformin
CA2864049A1 (en) Use of beta-nerve growth factor for inducing ovulation in mammals

Legal Events

Date Code Title Description
FG Grant or registration